Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective.

Autor:	Schultz KAP; Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN., Chintagumpala M; Division of Hematology-Oncology, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX., Piao J; University of Southern California Keck School of Medicine, Los Angeles, CA., Chen KS; Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX., Shah R; University of Southern California Keck School of Medicine, Los Angeles, CA.; Division of Hematology-Oncology, Department of Pediatrics, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA., Gartrell RD; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY., Christison-Lagay E; Yale School of Medicine, Yale New-Haven Children's Hospital, New Haven, CT., Pashnakar F; Department of Pediatrics, Yale University School of Medicine, New Haven, CT., Berry JL; University of Southern California Keck School of Medicine, Los Angeles, CA.; The Vision Center, Children's Hospital Los Angeles, The Saban Research Institute, Children's Hospital Los Angeles, USC Roski Eye Institute, Norris Comprehensive Cancer Center, Los Angeles, CA., O'Neill AF; Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA., Vasta LM; Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD., Flynn A; Hematology/Oncology, Children's Mercy Kansas City, Kansas City, MO., Mitchell SG; Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Department of Pediatrics, Emory University, Atlanta, GA., Seynnaeve BK; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA., Rosenblum J; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Westchester Medical Center, New York Medical College, Valhalla, New York, NY., Potter SL; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.; Department of Pediatrics, The Ohio State University, Columbus, OH., Kamihara J; Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA., Rodriguez-Galindo C; Departments of Global Pediatric Medicine and Oncology, St. Jude Children's Research Hospital, Memphis, TN., Hawkins DS; Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA., Laetsch TW; Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.
Jazyk:	angličtina
Zdroj:	EJC paediatric oncology [EJC Paediatr Oncol] 2023 Dec; Vol. 2. Date of Electronic Publication: 2023 Jul 20.
DOI:	10.1016/j.ejcped.2023.100024
Abstrakt:	While all childhood cancers are rare, tumors that are particularly infrequent or underrepresented within pediatrics are studied under the umbrella of the Children's Oncology Group Rare Tumor committee, divided into the Retinoblastoma and Infrequent Tumor subcommittees. The Infrequent Tumor subcommittee has traditionally included an emphasis on globally rare tumors such as adrenocortical carcinoma, nasopharyngeal carcinoma, or those tumors that are rare in young children, despite being common in adolescents and young adults, such as colorectal carcinoma, thyroid carcinoma, and melanoma. Pleuropulmonary blastoma, gonadal stromal tumors, pancreatic tumors including pancreatoblastoma, gastrointestinal stromal tumor, nonmelanoma skin cancers, neuroendocrine tumors, and desmoplastic small round cell tumors, as well as other carcinomas are also included under the heading of the Children's Oncology Group Rare Tumor committee. While substantial challenges exist in rare cancers, inclusion and global collaboration remain key priorities to ensure high quality research to advance care. Competing Interests: Conflicts of interest: Samara Potter reports a relationship with Bayer Healthcare that includes: consulting or advisory. Theodore Laetsch reports a relationship with Advanced Microbubbles that includes: consulting or advisory. Theodore Laetsch reports a relationship with AI Therapeutics that includes: consulting or advisory. Theodore Laetsch reports a relationship with Bayer that includes: consulting or advisory. Theodore Laetsch reports a relationship with GentiBio that includes: consulting or advisory. Theodore Laetsch reports a relationship with Jazz Pharmaceuticals that includes: consulting or advisory. Theodore Laetsch reports a relationship with MassiveBio that includes:. Theodore Laetsch reports a relationship with Menarini that includes: consulting or advisory. Theodore Laetsch reports a relationship with Novartis that includes: consulting or advisory. Theodore Laetsch reports a relationship with Pyramid Biosciences that includes: consulting or advisory. Theodore Laetsch reports a relationship with Treeline Biosciences, Inc. that includes: consulting or advisory. The remaining authors have no conflicts of interest to disclose.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu